Figure 1.
CRISPR/Cas9 gene editing and autologous transplantation of RMs. (A) Schematic diagram of an RM CRISPR/Cas9 gene editing/autologous transplantation model. RM HSPCs were mobilized into the blood with granulocyte colony-stimulating factor (G-CSF) and plerixafor (AMD3100). CD34+ cells were electroporated with ribonucleoprotein (RNP) complexes containing gRNAs targeting either a PIG-A exon or the AAVS1 safe harbor site and Cas9 protein. Edited cells were reinfused into the autologous macaque after total body irradiation. Long-term tracking of mutated cells was performed by targeted deep sequencing and flow cytometry. (B) Before transplantation, initial editing efficiency of PIG-A and AAVS1 in an infusion product was determined in both RMs by targeted deep sequencing. (C) Transplantation characteristics of RMs included in the study.

CRISPR/Cas9 gene editing and autologous transplantation of RMs. (A) Schematic diagram of an RM CRISPR/Cas9 gene editing/autologous transplantation model. RM HSPCs were mobilized into the blood with granulocyte colony-stimulating factor (G-CSF) and plerixafor (AMD3100). CD34+ cells were electroporated with ribonucleoprotein (RNP) complexes containing gRNAs targeting either a PIG-A exon or the AAVS1 safe harbor site and Cas9 protein. Edited cells were reinfused into the autologous macaque after total body irradiation. Long-term tracking of mutated cells was performed by targeted deep sequencing and flow cytometry. (B) Before transplantation, initial editing efficiency of PIG-A and AAVS1 in an infusion product was determined in both RMs by targeted deep sequencing. (C) Transplantation characteristics of RMs included in the study.

Close Modal

or Create an Account

Close Modal
Close Modal